{"id":"cytokine-induced-killer-cells-folfox4","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL5315108","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytokine-induced killer (CIK) cells are ex vivo expanded lymphocytes with natural killer and T-cell properties that recognize and kill tumor cells. When combined with FOLFOX4 (a chemotherapy regimen of 5-fluorouracil, leucovorin, and oxaliplatin), the chemotherapy reduces tumor burden while CIK cells provide immunological attack against remaining malignant cells, potentially reducing recurrence and improving overall survival.","oneSentence":"Cytokine-induced killer cells combined with FOLFOX4 chemotherapy work synergistically to enhance anti-tumor immunity and direct cytotoxic killing of cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:31:38.122Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (in combination with FOLFOX4 chemotherapy)"}]},"trialDetails":[{"nctId":"NCT03084809","phase":"PHASE4","title":"Chemotherapy Combined With CIK Treating Colon Cancer","status":"COMPLETED","sponsor":"China Meitan General Hospital","startDate":"2012-05-06","conditions":"Colorectal Cancer, Cytokine-induced Killer Cells, Postoperative Complications","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CIK + Oxaliplatin + leucovorin + 5-FU"],"phase":"marketed","status":"active","brandName":"Cytokine-induced killer cells+ FOLFOX4","genericName":"Cytokine-induced killer cells+ FOLFOX4","companyName":"China Meitan General Hospital","companyId":"china-meitan-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cytokine-induced killer cells combined with FOLFOX4 chemotherapy work synergistically to enhance anti-tumor immunity and direct cytotoxic killing of cancer cells. Used for Colorectal cancer (in combination with FOLFOX4 chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}